鴨胚胎干細胞

Cat No.: NTCC594256

BioVector NTCC質(zhì)粒載體菌種細胞蛋白抗體基因保藏中心

鴨胚干細胞已被多家生物制藥公司用于醫(yī)用及獸用治療性滅活/減毒病毒及治療性疫苗生產(chǎn)。多于20類家族的病毒已被證實可在EB66細胞中繁殖擴增，截止目前已有60多種治療性疫苗正在通過鴨胚胎干細胞細胞進行研發(fā)生產(chǎn)，已獲批的第一個使用鴨胚胎干細胞細胞生產(chǎn)的疫苗是H5N1流感疫苗。

Group: Bird cell line.

Group: Vaccine production cell line.

Species of origin：

Anas platyrhynchos (Mallard) (Anas boschas)

Breed/subspecies: GL30.

Sex of cell Male

Category Embryonic stem cell

Publications

PubMed=20562528

Olivier S., Jacoby M., Brillon C., Bouletreau S., Mollet T., Nerriere O., Angel A., Danet S., Souttou B.,

Guehenneux F., Gauthier L., Berthome M., Vie H., Beltraminelli N., Mehtali M.

Avian Vaccine production cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic

monoclonal antibodies with enhanced ADCC activity.

MAbs 2:405-415(2010)

PubMed=21502045

Brown S.W., Mehtali M.

The Avian Vaccine production cell line  cell line, application to vaccines, and therapeutic protein production.

PDA J. Pharm. Sci. Technol. 64:419-425(2010)

Description:

The Avian Vaccine production cell line  is a proprietary embryonic stem cell-based technology for the production of a wide variety of human and

veterinary viral and therapeutic vaccines.

It can be used for the manufacturing of inactivated viruses, live attenuated viruses, live vectors, and subunit vaccines.

Today, more than 20 different families of viruses have been shown to efficiently propagate in Avian Vaccine production cell line  and more than 60

human and veterinary Avian Vaccine production cell line based vaccines are currently being developed utilizing the technology in R&D and clinical phases.

The first veterinary vaccine produced in E-66 cells obtained licensure in September 2012 and the H5N1 adjuvanted pandemic

Influenza vaccine produced by the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) in collaboration with GSK is

currently in a New Drug application (NDA)-Phase in Japan.